Articles related to LUNG CANCER

A phase II study of durvalumab alone or combined with the anti-CD73 monoclonal antibody oleclumab or anti-NKG2A monoclonal antibody monalizumab as consolidation therapy in patients with unresectable stage III NSCLC and no progression after concurrent chemoradiotherapy. With a median follow-up of 11.5 months, both combinations increased ORR and prolonged PFS versus durvalumab alone. Safety was similar across arms with no new or significant safety signals identified with either combination.

An 87-year-old white man presented to a hospital emergency surgical department with two round, grayish-brown nodules on his abdomen. He had no other complaints except feeling tired and dizzy for the last few months. He had a 120 pack-year smoking history but was not taking any medications and had not experienced a cough, chest pain, shortness of breath, or other breathing problems.

Compared to chemotherapy alone, adebrelimab plus chemotherapy nearly doubled 2-year OS and more than tripled 1-year PFS in patients with extensive-stage SCLC, according to results presented earlier this month at the AACR Annual Meeting 2022. The phase 3 CAPSTONE-1 study evaluated adebrelimab in combination with carboplatin plus etoposide, as first-line treatment for ES-SCLC.

This retrospective cohort study included 2,833 patients with stage IB to IIIA NSCLC who enrolled in the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) screening study from August 18, 2014, to April 1, 2019. Although 93% received surgical resection, just 53% had adequate lymph node dissection and 57% received any adjuvant chemotherapy. The authors suggest more effort at optimizing use of proven therapies in this patient population.

This study evaluates the effect of including a patient-reported electronic symptom scoring system in terms of outcomes. Symptoms scored included pain, fatigue, disturbed sleep, shortness of breath, and coughing. The intervention group reported fewer symptom threshold events than the control group in hospital and 4 weeks post discharge.

In March 2021, the US Preventive Services Task Force expanded the eligibility for lung cancer screening by setting the benchmark at a 20 pack-year smoking history for those ages 50 to 80 years who are current smokers or former smokers who have quit within the past 15 years. The new criteria will boost the number of eligible adults by 87% overall, according to a modeling analysis. It also could reduce lung cancer deaths by 13% versus 10% previously.